Literature DB >> 8070426

Disorders of steroid 17 alpha-hydroxylase deficiency.

C E Kater1, E G Biglieri.   

Abstract

The human P450c17 alpha gene (CYP17) is a single copy gene located in chromosome 10, consisting of 8 exons and 7 introns. 17 alpha-Hydroxylase/17,20-lyase deficiency is one of two hypertensive forms of congenital adrenal hyperplasia and is inherited as an autosomal recessive trait; although rare, it probably exists with twice the frequency of the 11 beta-hydroxylase deficiency. Deficient 17 alpha-hydroxylation of pregnenolone and progesterone and subsequent deficiency of the cleavage of the C-17,20 carbon bond result in the absence of sex hormone formation in both the adrenal glands and the gonads, causing hypogonadism and male pseudohermaphroditism. Elevated and glucocorticoid-suppressible levels of the ZF 17-deoxysteroids--DOC and corticosterone--as well as their 18-hydroxylated products--18-OHDOC and 18-OHB (in addition to 19-nor-DOC)--are responsible for hypertension, hypokalemia, and renin and aldosterone suppression. A few cases, reported primarily among Japanese families, have basal hyperaldosteronism, an enigmatic condition that still demands adequate explanation. Like other forms of congenital adrenal hyperplasia, treatment of 17 alpha-hydroxylase deficiency consists of replacement doses of glucocorticoid hormones and supplemental estrogen therapy in the young adult patient. Heterozygotes may be detected by slightly exaggerated responses of some or all the ZF 17-deoxysteroids to ACTH stimulation, and by the elevated ratio of total urinary metabolites of corticosterone to the total metabolites of cortisol.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8070426

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  30 in total

1.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

Review 2.  Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic.

Authors:  Richard J Auchus
Journal:  J Steroid Biochem Mol Biol       Date:  2016-02-06       Impact factor: 4.292

Review 3.  17 Alpha-hydroxylase deficiency.

Authors:  E G Biglieri
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

4.  Catalytically relevant electrostatic interactions of cytochrome P450c17 (CYP17A1) and cytochrome b5.

Authors:  Hwei-Ming Peng; Jiayan Liu; Sarah E Forsberg; Hong T Tran; Sean M Anderson; Richard J Auchus
Journal:  J Biol Chem       Date:  2014-10-14       Impact factor: 5.157

Review 5.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

Review 6.  Miscellaneous endocrine causes of hypertension.

Authors:  Richard J Auchus
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

Review 7.  Hereditary causes of primary aldosteronism and other disorders of apparent excess mineralocorticoid activity.

Authors:  Xin He; Zubin Modi; Tobias Else
Journal:  Gland Surg       Date:  2020-02

8.  17alpha-hydroxylase deficiency : biochemical and molecular findings in two sisters and their family.

Authors:  Maria S Perez; Haydee Benencia; Gustavo D Frechtel; Eduardo O Esteban; Maria Christina Gil; Héctor M Targovnik; Norma B Marquez
Journal:  Mol Diagn       Date:  2004

9.  Familial partial 17,20-desmolase and 17alpha-hydroxylase deficiency presenting as infertility.

Authors:  David Levran; Izhar Ben-Shlomo; Clara Pariente; Jehoshua Dor; Shlomo Mashiach; Ariel Weissman
Journal:  J Assist Reprod Genet       Date:  2003-01       Impact factor: 3.412

Review 10.  Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.

Authors:  Sara S Roscioni; Dick de Zeeuw; Stephan J L Bakker; Hiddo J Lambers Heerspink
Journal:  Nat Rev Nephrol       Date:  2012-10-16       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.